Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

ore tax expenses (income)

(4,903)

(3,115)

(14,280)

(13,649)Tax Expenses (income)

(18)

25

31

7Net Loss$(4,885)

$(3,140)

$(14,311)

$(13,656)Net loss per share – basic and diluted

$(0.27)

$(0.18)

$(0.81)

$(0.82)Weighted average number of shares of common stock used in computing net loss per share – basic and diluted

18,196,083

17,044,737

17,662,175

16,596,379 CONSOLIDATED BALANCE SHEETS (2)
(U.S. dollars in thousands)ASSETSMarch 31,
2013June 30,
2012Current Assets:Cash and cash equivalents

$2,514

$10,284Restricted cash

91

37Accounts receivable:Trade

2,146

1,824Other

278

264Prepaid expenses

91

93Inventory:On hand

1,982

1,744On consignment63Total current assets7,102

14,309Property, plant and equipment, net of accumulated depreciation and amortization

467

462 

Other non-current assets:Deferred issuance costs

951

961Funds in respect of employee rights upon retirement

380

282Royalties buyout

897Total other non-current assets2,228

1,243Total assets$9,797

$16,014 LIABILITIES AND EQUITYMarch 31,
2013June 30,
2012Current liabilities:Accounts payable and accruals:Trade

$416

$441Other

2,885

2,925Advanced payment from customers

177

174Deferred revenues

10

10Convertible loan

7,385Total current liabilities10,873

3,550Long-term liabilities:Liability for employees rights upon retirement

495

354Convertible loan5,018Contingently redeemable warrants and others

1,832

1,706Total long-term liabilities2,327

7,078Total liabilities13,200
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  By looking at ... to distinguish between two very different conditions that ... Theodore Henderson , MD, PhD., a ... cases, this study can help the ... therefore treatment options, for Post-Traumatic Stress Disorder (PTSD) ...
(Date:5/4/2015)... 2015  CytRx Corporation (Nasdaq: CYTR ), ... oncology, today announced an interim analysis from its ... aldoxorubicin with either gemcitabine or ifosfamide. Both studies ... escalating doses of aldoxorubicin. The combinations appear to ... dose level of aldoxorubicin (170 mg/m2), impressive tumor ...
(Date:5/4/2015)... CONCORD, N.H. , May 4, 2015 /PRNewswire/ ... creating analytic and technology solutions to improve healthcare ... Bedford Nursing & Rehabilitation Center (BNRC) use ... monitoring platform to improve the quality and lower ... analytics platform integrates clinical, outcomes, claims and utilization ...
Breaking Medicine Technology:New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: ... developer, manufacturer and seller of medicine and drugs in the ... four members of its board of directors and the subsequent ... Mr. Lijun Fan, Mr. Zhaohui Li, and Mr. Jun Lu ...
... Dec. 21, 2010 Silence Therapeutics plc (AIM: SLN) ... dedicated to the discovery, development and delivery of targeted, ... serious diseases, today provides a year-end update on trading ... Silence Therapeutics, comments: "2010 has been an exciting ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Change of Directors 2Lotus Pharmaceuticals Announces Change of Directors 3Lotus Pharmaceuticals Announces Change of Directors 4Silence Therapeutics Provides Year-end Update 2Silence Therapeutics Provides Year-end Update 3
(Date:5/4/2015)... SACRAMENTO, Calif. (PRWEB) May 04, 2015 ... Permanente Medical Group today launched a new initiative ... building the next generation of physicians committed to ... Estudiantes Para Ser Medicos, or Preparing Students to ... multi-faceted initiative that will provide scholarships, mentorship and ...
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... R.I. (PRWEB) May 04, 2015 Johnson & ... $40 million engineering and science academic center on Wednesday, April ... the ground for land made available by the re-alignment of ... the corner of Friendship and Chestnut streets in Providence, is ... built on a parcel of land the university purchased in ...
(Date:5/4/2015)... 04, 2015 The Lymphoma Research Foundation ... to funding innovative lymphoma research and serving the lymphoma ... initiatives and patient services – is set to host ... Farms in West Orange, NJ on June 1, 2015. ... innovative research programs through LRF. , This year, the ...
(Date:5/4/2015)... 04, 2015 Baptist Medical Center ... Association’s Get With The Guidelines®-Stroke Gold Plus Quality ... Roll. The award recognizes the hospital’s commitment and ... most appropriate treatment according to nationally recognized, research-based ... To receive the Gold Plus Quality Achievement Award, ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... a strain of HIV that is extremely hard to treat, ... ,At least two types of HIV drugs don't work ... from Public Health — Seattle & King County said Thursday. ... the gay community is at highest risk," said Dr. Bob ...
... genes from an ancient wheat variety have led to a ... a recent set of papers published in the journal Plant ... and Nax2. The genes work by excluding salt from different ... from the leaves. The discovery of the two genes is ...
... has continued to decrease since the early 1990s, the rate ... percent higher in African American women than in white men ... ,However, the disparity among men has narrowed over ... African Americans than whites. These data appear in the newly ...
... increase in allergic reactions among people who use hair dye, ... Teenagers appear to be more susceptible, as they are seen ... ,The common allergic reactions are rashes, facial swelling and ... ,Now researchers are pressing for a wider debate about ...
... being tired or exhausted, people should take these complaints ... or even death, says a University of Alberta researcher ... of A professor from the Faculty of Nursing, argues ... and that recognizing those distinctions will help health-care workers ...
... clinical practice guidelines for diagnosis and management of venous ... causes clotting in the veins. ,Key elements ... prediction rules to establish pretest probability of deep vein ... testing and the utility of various diagnostic tools such ...
Cached Medicine News:Health News:New HIV Threat Found in King County 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Cancer Death Rates High in African-Americans 2Health News:Take Fatigue Seriously - Says Researcher 2Health News:Take Fatigue Seriously - Says Researcher 3Health News:New Guidelines for Diagnosis of Venous Thromboembolism 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: